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Therapeutic strategies for advanced
neuroendocrine carcinomas of
jejunum/ileum and pancreatic origin
Christoph J Auernhammer, Burkhard Göke
ABSTRACT
Multimodal treatment options for advanced
gastroenteropancreatic neuroendocrine tumours (NET) of
jejunum/ileum and of pancreatic origin are reviewed.
Current topics being discussed are: European
Neuroendocrine Tumour Society 2006/7, American Joint
Cancer Committee/Union Internationale Contre le Cancer
2009 and WHO 2010 recommendations for grading and
staging of NET; surgery of the primary tumour in distant
metastasised disease; surgery of metastatic liver disease
and impact on survival; somatostatin analogues for
symptom control and for tumour control; selective
internal radiation therapy with 90Y-microspheres as
novel local ablative therapy in liver metastases; peptide
receptor radionuclide therapy; novel chemotherapy
regimens (eg, temozolomide) and novel targeted
therapies (eg, sunitinib and everolimus).
Neuroendocrine tumours (NET) of the gastro-
enteropancreatic system can originate from every
part of the gastroenteropancreatic system and have
been classified during the past decade as benign
well-differentiated NET, malignant well-differenti-
ated neuroendocrine carcinomas (NEC) and poorly
differentiated NEC.1e3 Specific hormone hyperse-
cretion-related functional syndromes (eg, carcinoid
syndrome, insulinoma, gastrinoma and others) are
only present in approximately 20e30% of all
patients with NET.4e6
National databases6e8 and tertiary referral
centres5 have shown that the primary tumour
location of NET of the gastroenteropancreatic
system is frequently in the jeunum/ileum or in the
pancreas with 16e29% or 31e34%, respectively.
NET in the jeunum/ileum and in the pancreas have
been shown to present at diagnosis with regional or
distant metastasised disease in 71e89% and
54e86% of cases, respectively.5e7 Therefore, from
an oncological point of view, NET of the jejunum/
ileum and of the pancreas are the most common
primary tumour entities of NEC within the
gastroenteropancreatic system.5e7
STAGING, GRADING AND PROGNOSTIC FACTORS
Numerous prognostic markers for gastro-
enteropancreatic NEThave been described.9 10 In the
clinical routine, important prognostic markers of
gastroenteropancreatic NET are primary tumour
localisation, tumour grading including proliferation
index Ki-67 (Mib-1), tumour staging and pattern of
hepatic tumour load.
NETof the pancreas have a poorer prognosis than
NET of the jejunum/ileum.5 7 NET of the pancreas
and NET of the jejunum/ileum accumulate
different patterns of genetic defects during tumour
transformation. They must thus be regarded as
different tumour entities.11 Both tumour entities
differ not only in their tumour biology but also in
their clinical behaviour and prognosis. In a total of
35 618 NET, registered in the Surveillance, Epide-
miology and End Results (SEER) Programme from
1973 to 2004, the median survival rate was
88 months in NET of the jejunum/ileum versus
42 months in pancreatic NET.7 Regional metastatic
disease was present in 41% of all NET of the
jejunum/ileum and in 22% of all pancreatic NET.
However, distant metastatic disease was present in
30% of all NETof the jejunum/ileum and in 64% of
all pancreatic NET. In NET of the jejunum/ileum
and in pancreatic NET 5-year survival rates were
71% versus 62% in regional metastatic disease and
54% versus 27% in distant metastatic disease.7 In
a single centre retrospective analysis of 104 ileum
and 98 pancreatic NET, Pape et al5 reported a 5-year
survival rate of 90% versus 69% and a 10-year
survival rate of 63% versus 62%. The beneficial
impact of large volume centres on survival
outcomes still needs to be assessed. Still this may
explain the different data from national registries
versus single large volume centre series.5 Bilimoria
et al12 reported data from the National Cancer Data
Base (1985e2004) of 3851 patients who underwent
surgery for pancreatic NET. Overall survival rate
was 59.3% at 5 years and 37.7% at 10 years.12 In
a multivariate Cox proportional hazard model,
highly significant negative prognostic factors were
high-grade histology (HR 2.03, 95% CI 1.41 to 2.92,
p<0.0001), liver metastases (HR 1.71, 95% CI 1.36
to 2.14, p<0.0001) and other distant metastases
(HR 3.78, 95% CI 1.51 to 9.43, p<0.0001).12 These
data thus reveal that NET have a poorer prognosis
than previously assumed and implied by the
historic term ‘carcinoid’.1 2
The historic term ‘carcinoid’ has been replaced
by the WHO classification 2000 for gastro-
enteropancreatic NET, which classifies tumours
according to their primary tumour site and
discriminates between benign well-differentiated
endocrine tumours and malignant well-differenti-
ated endocrine carcinomas and poorly differentiated
endocrine carcinomas.1e3 The WHO classification
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system 2000 envolved stage-related information
to discriminate between well-differentiated endo-
crine tumours and well-differentiated endocrine
carcinomas.1e3 The novel WHO classification
201013 14 assumes neuroendocrine neoplasms as
a category to be potentially malignant. The novel
histopathological grading system discriminates
NET G1 (carcinoid), NET G2, and NEC of small cell
and large cell type. In order to address the dignity
and prognosis of a neuroendocrine neoplasm, the
novel WHO classification 201013 14 combines
histopathological grading and tumour site-specific
tumourenodeemetastasis (TNM) staging. For
example, a local or distant metastasised NET G1/G2
according to WHO classification 2010, would have
been classified as well-differentiated NEC according
to WHO classification 2000. On the other hand,
a small cell or large cell NEC according to WHO
classification 2010 would have been classified as
poorly differentiated NEC according to WHO clas-
sification 2000. To avoid misunderstandings in
clinical routine, medical reports should name the
WHO classification system and the TNM classifi-
cation system used. The nomenclature of the
WHO classification system 2000 may still be used
in addition to the WHO classification system
2010.13 14 Nevertheless, in the current literature,
NET of the jejunum/ileum are still often termed
‘midgut carcinoid’, while NET of the pancreas are
still often named ‘islet cell tumour ’ or the WHO
classification 2000 has been used. Therefore, in this
review the term ‘neuroendocrine carcinoma’ is
still used to refer to well-differentiated endocrine
carcinomas in accordance with the literature cited.
The ENETS classification 2006/7,15 16 the 7th
American Joint Cancer Committee/Union Inter-
nationale Contre le Cancer (AJCC/UICC) classifi-
cation 200917e20 and the current WHO
classification 20103 13 19 all equally define a grading
system based upon the proliferation index Ki-67
and/or mitotic index with low-grade G1 tumours
(Ki-67 #2%, mitotic count <2 per 10 high-power
field; HPF), intermediate-grade G2 tumours (Ki-67
3e20%, mitotic count 2e20 per 10 HPF) and high-
grade G3 tumours (Ki-67 >20%, mitotic count
>20%). These three-tiered grading systems
including the proliferation index Ki-67 (Mib-1) and/
or the mitotic index have been demonstrated to be
high impact prognostic markers for NET.5 12 21e25
For example, in a series of 202 upper gastrointestinal
NET Pape et al23 demonstrated that G1 tumours
(Ki-67 #2%), G2 tumours (Ki-67 3e20%) and G3
tumours (Ki-67>20%) showed a 5-year survival rate
of 95.7%, 73.4% and 27.7%, respectively.23 The
prognostic importance of histopathological grading
has also been demonstrated in a series of 324
patients with pancreatic NET. In a multivariate
analysis, significantly negative prognostic markers
were a proliferation index Ki-67 greater than 2%
(HR 5.2, CI 95% 1.8 to 15.0, p¼0.002) or histologi-
cally poorly differentiated NEC (HR 9.9, CI 95% 2.9
to 34.0, p<0.001).21 Therefore, histopathological
grading including proliferation index Ki-67 is
essential for prognosis and is highly recommended
for the clinical routine.26 27
Several retrospective analyses from the Surveil-
lance, Epidemiology and End Results (SEER) data-
base and suggestions for a TNM classification
system for gastroenteropancreatic NET have
been published by Landry and colleagues.28e33 Two
official TNM classification systems for gastro-
enteropancreatic NET have recently been provided
by ENETS 2006/715 16 (http://www.neuroendo-
crine.net/) and by AJCC/UICC 7th edition (http://
www.uicc.org/resources/tnm).17 18 20 These two
TNM classification systems differ specifically in
the T stages for NET of the appendix and of the
pancreas.18 26 34 Pathologists as well as clinicians
should be aware of this circumstance and medical
reports should name the TNM classification system
being used. For the ENETS 2006/7 TNM classifi-
cation15 16 of pancreatic NET, several large series
have already demonstrated a good prognostic
discrimination,12 21e23 34 which might be even
further improved in the future.34
Distant metastatic disease is without doubt
a poor prognostic factor. The liver most frequently
resembles a metastatic dissemination site.5 24 35 36
Furthermore, the pattern and extent of hepatic
tumour load help to determine different treatment
options and prognosis in patients with liver
metastasis.35 37e39 In 118 patients with distant
metastasis from well-differentiated gastro-
enteropancreatic NEC, predictors of survival were
the number of initial diagnosed liver metastasis
Summary
Current standards
< Recent comprehensive guidelines for the diagnosis and treatment of
gastroenteropancreatic NET have been published by the European Neuroen-
docrine Tumour Society (ENETS), the National Comprehensive Cancer
Network (NCCN) and the North American Neuroendocrine Tumour Society
(NANETS).
< Surgery is the only curative option for NEC. Surgery of liver metastases and
debulking surgery are essential in NEC.
< Somatostatin analogues are important for symptom control of functionally
active NEC.
< Peptide receptor radionuclide therapy with 90Yttrium-DOTA-TOC, 90Yttrium-
DOTA-TATE and 177Lutetium-DOTA-TATE is a promising strategy in distant
metastases of NEC.
Novel findings and future perspectives
< Somatostatin analogues may be considered for antiproliferative treatment in
well-differentiated functional and non-functional NET of the jejunum/ileum.
< Temozolomide plus capecitabine is a novel promising chemotherapy protocol
in pancreatic NEC, which merits further evaluation.
< Selective internal radiation therapy with 90Y-microspheres is a novel local
ablative strategy in disseminated liver metastases.
< Novel targeted therapies with the mammalian target of rapamycin (mTOR)
inhibitor everolimus or the multikinase inhibitor sunitinib, both improve
progression-free survival in NEC of the pancreas. Sunitinib has been approved
by the European Medicines Agency (EMA) for this indication in 11/2010.
Everolimus may also be expected to get approved in the near future.
< Neoadjuvant and adjuvant therapeutic strategies for liver surgery of hepatic
metastasised NEC are urgently needed. Further research should address this
issue.
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(HR 3.4, 95% CI 1.4 to 8.3, p¼0.01) and initial
surgery (HR 0.3, 95% CI 0.1 to 0.8, p¼0.01).37 In
another series of 119 patients with hepatic metas-
tases of NEC,38 5 and 10-year survival rates were
100% both in the subgroup with single liver
metastasis, versus 84% and 75% in the subgroup
with isolated metastatic bulk accompanied by
smaller deposits, versus 51% and 29% in the
subgroup with disseminated metastatic spread.38
Interestingly, in the PROMID study a greater than
10% metastatic tumour load of the liver was
defined as a negative prognostic factor for tumour
response to biotherapy in 85 patients with non-
resectable metastasised NEC.35 In 310 patients
with non-resectable NEC, treated with 177Lute-
tium-DOTA-Tyr3-octreotate (177Lu-DOTA-TATE),
extensive liver involvement was found to be
a negative prognostic factor for survival after
peptide receptor radionuclide therapy (PRRT).39
The prognostic impact of clinically functional
versus non-functional tumours is controver-
sial.12 21 22 36 While some studies found no prog-
nostic effect of the functional status in NETof the
pancreas,21 36 others reported non-functional
tumours22 or vice versa functional tumours12 as
predictors of improved survival.
SURGERY OF THE PRIMARY IN LOCAL DISEASE
AND IN METASTASISED DISEASE
Surgery of NET is the sole curative option. Surgery
of the primary tumour may be also advantageous in
well-differentiated NEC with local lymph node and
distant liver metastasis according to concepts of
‘debulking’ for tumour mass reduction.
In NEC of the midgut, resection of the primary
has been reported to be an independent positive
predictor of survival.40 41 In a single centre study
series by Hellman et al41 in 314 patients with
midgut carcinoid tumours, the median survival was
7.4 years in the primary resected group versus
4.0 years in the primary non-resected group. In the
multicentre study UKINETS,40 with 360 patients
with midgut carcinoid tumours, resection of the
primary was an independent positive predictor of
survival. In contrast, no significant survival benefit
of primary tumour resection was reported in two
other series of metastatic NEC.24 35 Following total
surgery of midgut NET, tumour recurrence has been
observed in 59%, with a median time to recurrence
of 32 months.42 Resection of the primary tumour
with mesenteric lymph nodes due to oncological
criteria is also recommended in the presence of
unresectable liver metastasis in patients with well-
differentiated NEC of the jejunum/ileum by
guidelines from ENETS 2008,43 NCCN 200944 and
NANETS 2010.45 The rationale for this recom-
mendation is to avoid desmoplastic reaction with
bowel obstruction and/or bowel ischaemia reaching
a situation in which only the liver metastases need
further treatment.
In NEC of the pancreas, aggressive surgery of the
primary has also been reported not only in local but
also in distant disease with liver metastasis.46 In
a retrospective survival analysis of 728 patients
with pancreatic NET from the SEER database
(1988e2002), the median survival was 114 months
in the resected group versus 35 months in a non-
resected group, with an adjusted HR of 0.48.47 This
advantage in median survival was not only signifi-
cant in localised disease, but also in regional
metastasised disease (resection 129 months vs
resection recommended/not resected 64 months)
and distant metastasised disease (resection
60 months vs resection recommended/not resected
31 months).47 Data from the National Cancer Data
Base (1985e2004) on 3851 patients undergoing
surgery for pancreatic NET showed no significant
effect of primary tumour size, nodal status, resec-
tion margins or surgical procedure in a multivariate
Cox proportional hazard model.12 However,
a highly significant negative prognostic factor was
age 55e75 years (HR 1.57, 95% CI 1.28 to 1.91,
p<0.0001) and age greater than 75 years (HR 3.04,
95% CI 2.17 to 4.25, p<0.0001).12 The patient’s age
should thus be considered in clinical decision-
making when evaluating pancreatic surgery. In
several large surgical series of NEC of the pancreas,
morbidity and mortality ranged between 27e43%
and 0e3.4%, while 5-year survival rates for malig-
nant tumours were 49e77%.22 46 48e51 A post-
operative complication rate of 29.6% has been
reported in a nationwide inpatient sample survey
encompassing 463 patients after pancreatic surgery
from 1998 to 2006.52 Risk factors for complications
were a high Charlson comorbidity score as well as
Whipple operation or total pancreatectomy.52 The
potential benefits reported in a single uncontrolled
series47 may thus have been biased by patient
preselection and also need to be weighed up against
the morbidity and mortality of these surgical
procedures. Whereas for pancreatic NEC with
resectable liver metastases complete resection of
the primary and the liver metastases is recom-
mended by various guidelines,44 53 a primary
tumour resection of the pancreas is not recom-
mended in current guidelines for patients with
unresectable disseminated liver metastasis.53 54
SURGERY OF LIVER METASTASES
Surgery of synchronous or metachronous liver
metastases in well-differentiated NEC is recom-
mended when complete resection or debulking
more than 90% of the tumour load seems feasible.55
In patients with extended bilobar liver metastases,
the feasibility of a two-step resection should be
evaluated in an experienced centre.55 56 Using the
two-step approach non-anatomical limited resec-
tion of liver metastases in the left liver plus right
portal vein ligation is followed consecutively by
right hemihepatectomy after an adequate hyper-
trophy of the left liver has been reached.55 56 In
a large retrospective, multicentre series of 339
patients with NET liver metastases following
surgery of liver metastases the 5 and 10-year
survival rates were 74% and 51%,57 indicating
a prolonged survival. However, 5-year tumour
recurrence in several series has been reported in up
to 94%57 to 97%,58 indicating a non-curative
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approach in most cases. Complete and/or debulking
cytoreductive surgery of liver metastases has also
been reported as a positive predictor of survival in
several other retrospective uncontrolled series.40 59 60
However, so far, there is no evidence from rando-
mised studies comparing surgery of liver metastases
versus other treatments in patients with liver
metastases from NET.61 62 Sarmiento and Que60
reported in a large series of 170 patients with NEC
after surgery of liver metastases (44% curative
resection, 56% debulking >90% of tumour load)
a 5-year survival rate of 61% and, nevertheless,
a 5-year tumour recurrence rate of 84%. Similarly,
in a single-centre series of 41 patients with hepatic
metastasised NEC, tumour recurrence following
liver surgery was reported in 78% of cases after
a median of 19 months.58 Osborne et al59 compared
in another series of 120 patients surgery of liver
metastases (60% curative resection, 40% palliative
cytoreduction) versus transarterial embolisation
(TAE), with a mean overall survival of 43626
months versus 24616 months.
At present only single case reports or small
uncontrolled series describe neo-adjuvant strategies
with radio-receptor (90)Y-DOTATOC therapy,63
resin (90)Y-microspheres radio-embolisation64 or
chemotherapy for downsizing hepatic metastasis
of NEC before liver surgery. Neo-adjuvant strate-
gies are not yet established in liver surgery of
NEC. Adjuvant chemotherapy after resection of
neuroendocrine liver metastasis is also not estab-




When surgery seems unfavourable, radiofrequency
ablation (RFA) of liver metastasis in NEC may be
considered in metastases of fewer than five lesions
and metastases with a size less than 5 cm.66 RFA
results in a symptomatic response with a better
control of functional syndromes due to specific
hormone excess in approximately 70e80%67e69
and a duration of symptom control of 6e24
months.67 69 Local tumour recurrence following
RFA occurred in only 6% of NEC,68e70 while local
tumour recurrence tended to occur more often in
metastases with a higher Ki-67.68 The local recur-
rence rate following RFA of liver metastasis is
dependent on the respective tumour type, as has
been reported in a large series of 1032 unresectable
liver tumours. Local recurrence rates have been
reported as follows: 6% in NEC; 18% in hepato-
cellular carcinomas; and 34% in colorectal cancer.70
Further important prognostic factors for local
tumour recurrence following RFA of liver metas-
tases are tumour size, ablation margin, and blood
vessel proximity.70 No controlled data on overall
survival following RFA and comparison of RFA
with other local ablative methods are currently
available. Side-effects and complications of RFA
include pain, bile leakage, liver abscess, intra-
abdominal haemorrhage, pneumothorax and
pleural effusion.69 71 72
TAE and transarterial chemo-embolisation
(TACE) may be discussed for patients with liver
metastasis in cases of NEC for all inoperable
disseminated hepatic metastases. TAE and/or
TACE of liver metastasis in NEC results in
morphological response of the metastases with
mostly partial tumour regression in approximately
50%, a biochemical response of 50e90%, and
symptomatic response with a control of functional
syndromes in 60e95% of cases, as has been exten-
sively reviewed.66 71 73 74 Arterial phase enhance-
ment is a positive predictive factor of tumour
response.75 TAE and TACE seem to be equally
efficacious in the treatment of liver metastasis in
NEC.66 73 76 While many different protocols have
been reported in uncontrolled series for TAE and/or
TACE,66 71 74 no single protocol shows confirmed
superiority. Most centres recommend repeated
sessions of TAE or TACE.66 A biochemical response
measured by a reduction of urinary 5-hydroxy-
indolic acetic acid (5-HIAA) and serum chromog-
ranin A levels after TAE seems to correlate posi-
tively with prolonged survival in a recent series of
107 patients with liver metastasis of midgut carci-
noid tumours.77 A common side-effect of TAE and/
or TACE is a post-embolisation syndrome with
abdominal pain, nausea, vomiting, fever and an
increase in hepatic transaminases.71 74 75 Severe but
rare complications are liver failure, cholecystitis,
gastric ulcers and bleeding, liver abscess or carcinoid
crisis.71 74 75 The incidence of severe complications
is minimised by superselective catheterisation,
embolisation of a limited number of liver segments
during a single intervention in cases with high
tumour load of the liver and pretreatment with
a somatostatin analogue in functionally active
tumours.71 74 75 Current clinical phase II trials
are investigating drug-eluting beads with doxoru-
bicin for TACE in NEC78 79 (http://ClinicalTrials.
gov/ identifier: NCT00730483) and a combination
of TACE with the multikinase-inhibitor sunitinib
in NEC (http://ClinicalTrials.gov/ identifier:
NCT00434109). A combination of TAE or TACE
with inhibitors targeting angiogenesis or receptor-
associated kinases seems an attractive strategy as
embolisation of tumour tissue might cause a flair-
up of different growth factors including vascular
endothelial growth factor (VEGF).
RADIO-EMBOLISATION WITH 90Y-MICROSPHERES
Selective internal radiation therapy (SIRT) by
radio-embolisation of liver metastases with radio-
active 90Y-resin microspheres (SIR-Sphere; SIRTEX
Medical, Wilmington, USA) or 90Y-glass micro-
spheres (TheraSphere; MDS Nordion, Ottawa,
Canada) is currently employed to treat inoperable
disseminated hepatic tumours in patients with
hepatocellular carcinoma, colon cancer, breast
cancer and NEC. SIR-Sphere microspheres are
20e60 mm in diameter and the radioactivity load is
only approximately 50 Bq per single microsphere.
Approximately 30e603106 SIR-Sphere micro-
spheres are implanted and create a profound
embolisation effect. TheraSphere microspheres are
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also 20e30 mm in diameter, but the radioactivity
load is much higher with approximately 2500 Bq
per single microsphere. As significantly lower
numbers of TheraSphere microspheres are required
to reach equivalent radiation dosages, the emboli-
sation effect is only minor. SIR-Sphere is approved
as a medical device for the treatment of liver
metastasis from colon carcinoma in the USA,
Australia and Europe. TheraSphere is approved as
a medical device for treatment in patients with
unresectable hepatocellular carcinoma in the USA,
Canada and Europe. Both applications are expen-
sive and reimbursement varies regionally. Kennedy
et al80 reported in a large multicentre series of
148 patients with liver metastases of NEC, SIRT
by radio-embolisation with 90Y-resin microspheres
(SIR-Sphere) to deliver a median activity of
1.14 GBq (0.33e3.30 GBq). Within 3 months,
a complete tumour response was found in 2.7%,
a partial response in 60.5%, stable disease in 22.7%
and progressive disease in 4.9%.80 The median
survival was 70 months.80 Using SIRT with 90Y-
resin microspheres in a smaller series of 34 patients
with NEC, King et al81 reported symptomatic
responses in approximately 50% of all patients and
radiological tumour response in 50% (complete
response in 18% and partial response in 32%). A
biochemical response of the tumour marker chro-
mogranin A was found in approximately 40%.81
The mean overall survival was 2963 months.81
Rhee et al82 reported in another series of 42 patients
with NEC treated with radioactive 90Y-resin
microspheres (SIR-Sphere) or 90Y-glass micro-
spheres (TheraSphere) a tumour response within
6 months of approximately 90% (partial response
in 50e54% and stable disease in 42e44%) and
a projected median survival of 22e28 months. Cao
et al83 reported in a recent series of 51 patients with
NEC treated with SIRT 11% complete response,
27% partial response, 27% stable disease and 33%
progressive disease. Median survival in that series
was 36 months.83 Similarly, Kalinowki et al84
presented in a small series of nine patients with
NEC after radioactive 90Y-resin microspheres
(SIR-Sphere) a tumour response within 3 months
of 66% partial response and 33% stable disease,
with an estimated time to progression (TTP) of
11 months. Well-differentiated NEC, low hepatic
tumour burden, no extrahepatic disease and partial/
complete response to SIRT are prognostic factors
associated with improved survival;83 85 thus these
parameters may be useful for appropriate patient
selection. Clinicians should be aware of specific
complications of radio-embolisation with 90Y-
microspheres, such as radiation-induced liver
disease,86 hepatic abscess,87 arterial shunting to the
lung, radiation microsphere-induced gastric ulcera-
tion and bleeding, acute cholecystitis or acute
pancreatitis.88 89
So far, SIRTwith 90Y-microspheres demonstrates
radiological tumour response rates and symptom-
atic response rates within the range of non-radio-
active embolisation techniques such as TACE and
TAE in NEC. Still, the superiority of SIRT versus
TACE/TAE in NEC may only be assumed based
upon theoretical considerations. A significantly
improved tumour response has only been published
in a single study in hepatocellular carcinoma.90
Controlled studies of SIRT versus TACE/TAE are
needed in NEC.
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
PRRT of NEC has already been extensively
reviewed.91e95 PRRT is currently based on labelled
somatostatin analogues with high affinity to the
somatostatin receptor subtype 2, being expressed
by 80e95% of all NET. The currently most
frequently used radiopharmaceuticals for PRRT of




Adequate tumour uptake in 111In-DTPA-octreo-
tide (111In-pentetreotide) scintigraphy (Octreoscan;
Covidien - Mallinckrodt Imaging, Hazelwood, MO
63042, USA) is an essential prerequisite when
considering PRRT as a therapeutic option.96 Novel
somatostatin-based positron emission tomography
(PET) imaging techniques such as 68Ga-
DOTATOC-PET or 68Ga-DOTATATE-PET97 are
also increasingly used to evaluate adequate tumour
uptake before PRRT. Somatostatin receptor subtype
2 immunohistochemistry only modestly correlates
with the in-vivo standardised uptake values (SUV)
in diagnostic 68Ga-DOTATOC-PET98 and 68Ga-
DOTATATE-PET.99 A pre-therapeutic high inten-
sity of tumour uptake in 111In-DTPA-octreotide
scintigraphy (Octreoscan)39 95 seems to be a posi-
tive predictor of tumour remission in PRRT. Simi-
larly, significantly higher SUVmax of NET in pre-
therapeutic 68Ga-DOTATATE-PET has been
observed in responders versus non-responders to
PRRT.100 Even 111In-DTPA-octreotide scintigraphy
(OctreoScan) negative tumours frequently still
demonstrate specific uptake in 68Ga-DOTATATE-
PET101 and thus finally might qualify for PRRT.
The potential value of these specific PET/CT
techniques as a functional imaging modality to
predict early tumour response in the follow-up
after PRRT is not confirmed102 and still needs
further studies.100
Preclinical data providing important insights into
the principles of PRRT have been published with
human midgut GOT1 tumours in a mouse xeno-
graft model.103 104 Several uncontrolled clinical
studies investigating PRRT with 90Y-DOTA-
TOC,93 105e107 90Y-DOTA-TATE93 108 and 177Lu-
DOTA-TATE39 have been published (see table 1).
Kwekkeboom et al39 investigated PRRTwith 177Lu-
DOTA-TATE in the largest published series of 310
patients with NEC. Treatment with 177Lu-DOTA-
TATE caused a complete response in 2%, a partial
response in 28%, a minor response in 16%, stable
disease in 35% and progressive disease in 20%.39
The reported median progression-free survival (PFS)
rate was 33 months and the median overall survival
rate from the start of PRRT was 46 months.39
However, in that study only 43% of all patients had
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documented progressive disease before PRRT
treatment. Disease-specific survival was greater
than 48 months in patients with tumour remission
or stable disease as treatment response to PRRT,
while progressive disease was associated with only
11 months (p<0.01).39 Disease-specific survival was
also significantly and negatively affected in patients
with extensive liver involvement, Karnofsky
performance status less than 70%, weight loss and
bone metastases, as well as functional activity of
pancreatic NEC.39 These data suggest that treat-
ment with PRRT might be beneficial at an early
stage of disease. However, in contrast to this, most
centres use PRRT in pretreated patients with an
advanced tumour stage. Due to limited data and no
randomised controlled studies on the efficacy and
possible long-term side-effects of PRRT, its current
application is mostly restricted to a second or third-
line therapy. Patients who have initial benefit from
PRRT with 177Lu-DOTA-TATE but have tumour
progression later on, may benefit from a second
PRRTwith 177Lu-DOTA-TATE as salvage therapy.109
Side-effects of PRRT have been reported by
Kweekeboom et al39 in 510 patients treated with
177Lu-DOTA-TATE such as haematological
toxicity grades 3 and 4 in 9.5%, myelodysplastic
syndrome in 0.8%, renal toxicity grade 4 in 0.4%,
severe liver toxicity in 0.6% and the occurrence of
a carcinoid crisis in 1%. Renal toxicity is lower with
177Lutetium than with 90Yttrium.110 Long-term
renal toxicity has been calculated to result in a loss
of creatinine clearance per year of 3.8% following
177Lu-DOTA-TATE and of 7.3% following 90Y-
DOTA-TOC.110 111 Both bone marrow and liver
toxicity primarily result from a cross-radiation dose
of adjacent tumour tissue.39 112 DOTATATE and
DOTATOC have been granted orphan drug status
by the European Medicines Agency and the US
Food and Drug Administration.94 113 However,
PRRT is currently not available in the USA.45 113
Permission for PRRT in several European countries
is based on national legislation,96 radio-pharmaceu-
ticals are produced by local centres following good
manufacturing practice (GMP) regulations and
reimbursement varies regionally. PRRT is provided
by an increasing number of clinical centres in
Europe, and PRRTstandards for care guidelines have
recently been published by ENETS.96 No single-
centre individual protocol has confirmed superiority.
The maximum tolerated cumulative dose to the
kidney has been defined as 27 Gy.96 The adminis-
tration of amino acid infusions with arginine/lysine
is the current standard protocol during PRRT
treatments.96 This minimises re-uptake of the radio-
pharmaceutical in the renal tubulus causing a mini-
mised radiation dosage to the kidneys.114 115
The side-effects of PRRT might be further
minimised in the future by using novel radionu-
clides such as the alpha-emitter 225actinum,116 or
novel nephroprotective agents.114 117 One major
exclusion criterion for PRRT is insufficient renal
function. While a creatinine clearance greater than
40 ml/min has been suggested as a cut-off for
PRRT,96 we recommend an even more restrictive
cut-off. In patients who do not qualify for PRRT
due to impaired renal function or insufficient
tumour uptake of radiopharmaceuticals with
somatostatin receptor affinity, systemic radio-
therapy with 131I-meta-iodobenzylguanidine
should be evaluated and considered as an alterna-
tive therapeutic option.45 118e120 Strategies to
improve further the therapeutic efficacy of PRRT
in future include a combination of PRRT with
chemosensitisers such as 5-fluorouracil,121 capeci-
tabine122 or temozolomide.123
EVALUATION OF TREATMENT EFFICACY IN NEC:
LIMITATIONS AND FUTURE REQUIREMENTS
The efficacy of different therapeutic strategies in
NEC is difficult to compare due to the lack of
randomised head-to-head studies. The interpreta-
tion and comparison of various published study
results in NEC are often hampered by small patient
numbers and heterogeneous inclusion criteria
(eg, time since diagnosis, progressive versus non-
progressive disease, tumour grading, tumour
staging, primary tumour location, resected vs non-
resected primaries, low vs high hepatic tumour
load). Data on treatment outcomes from different
studies are thus not directly comparable and must
be interpreted with caution. In addition, prospec-
tive placebo controlled or standard controlled
studies are still missing and are urgently needed in
order to demonstrate a beneficial effect on the
overall survival and quality of life in patients with
NEC for most therapeutic strategies.
In addition, the efficacy of chemotherapeutic
regimens in solid tumours has been classically
assessed by a change in tumour size using the
WHO criteria, the RECIST criteria or the modified
RECIST (version 1.1.) criteria.124 125 However, most
novel anti-angiogenic and molecular targeted ther-
apies in solid tumours cause inhibition of tumour
growth rather than regression of tumour size.
Therefore, these novel therapies often show low
response rates by RECIST criteria, despite their
















Otte 1999a 18 NA e 6 83 11 NA
Waldherr 2001b 37 81 3 24 62 11 TTP>26
Waldherr 2002c 37 100 3 19 70 8 NA
Paganelli 2002d 87 76 5 23 49 20 TTP 14
Bodei 2003e 20 NA e 30 50 20 TTP 10
Valkema 2006f 58 76 e 9 62 24 TTP 29
Forrer 2006106 116 93 4 22 62 11 NA
Cwikla 2010108 60 100 e 23 70 0 PFS 17
90Y-DOTA-TATE
Baum 2004g h 75 89 e 37 52 11 NA
Bushnell 2010105 90 100 e 4 70 12 PFS 16
177Lu-DOTA-TATE
Kwekkeboom 200839 310 43 2 28 50 20 PFS 33
Adopted from Forrer et al93 and van Essen et al.91
CR, complete remission; PFS, progression-free survival; PD, progressive disease; PR, partial remission; SD,
stable disease; TTP, time to tumour progression.
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clinical benefit. As tumour size regression is not
a prerequisite of clinical benefit, criteria solely based
on tumour size regression have low prognostic
value. Perfusion CT, dynamic contrast-enhanced
MRI and FDG-PET response criteria in solid
tumours (PERCIST) criteria are emerging novel
strategies for functional imaging of solid tumours
and prognostic assessment of therapeutic
response.125 126 Contrast-enhanced CT can also
provide more information than the sole tumour
size. For example, the Choi criteria (size and
density of the tumour) in gastrointestinal stroma
tumours127 and the MASS criteria (morphology,
attenuation, size and structure of the tumour) in
renal cell carcinomas128 have superior prognostic
value during targeted therapy of these tumour
entities. Novel radiological criteria for response
assessment of NEC have not yet been established.
However, novel criteria are urgently needed for
prognostic stratification following novel targeted
therapies as well as biotherapy, peptide receptor
radionuclide therapy or local ablative techniques.
Tumour size measurement according to RECIST
criteria does not reflect the possible therapeutic
benefit of these therapies in NEC. Data based on
tumour regression are not always sufficient to
compare the efficacy of different therapeutic strat-
egies. Instead, TTP or PFS are alternatively often
determined in current studies with novel targeted
therapies. TTP or PFS measure the biological
activity of cytostatic as well as cytotoxic therapies
on tumour burden. They are important parameters
to evaluate the biological activity of novel therapies
in tumour patients and gain an accelerated approval
endpoint.129 However, TTP and PFS may not
provide reliable evidence that a novel therapy is also
of clinical efficacy for the patient.129 Clearly, overall
survival data are needed. However, multimodal and
multisequence treatment strategies in NEC will
make it difficult to obtain sufficient study data
employing overall survival as the primary endpoint
in future. A novel integrated approach is needed to
evaluate therapeutic efficacy efficiently.130 This
approach will have to include functional imaging
and biomarkers9 131 as prognostic indicators, as well
as PFS, quality of life132 and overall survival.
BIOTHERAPY WITH SOMATOSTATIN ANALOGUES
AND INTERFERON
Somatostatin analogues
Two somatostatin analogues, octreotide and
lanreotide, are currently approved by the European
Medicines Agency for symptom control of func-
tionally active NET133 134 as well as for acro-
megaly.135 A current review by Modlin et al134
analysed a total of 15 studies including 481 patients
with NET. In patients treated with octreotide
(n¼261), octreotide LAR (n¼122), lanreotide
(n¼30) and lanreotide autogel (n¼185), a symp-
tomatic response was seen in 74.2%, 77.3%, 63.0%
and 67.5%, respectively.134 Biochemical response
rates were reported with octreotide (n¼315),
octreotide LAR (n¼73), lanreotide (n¼49) and
lanreotide autogel (n¼333) in 50.9%, 51.4%, 55.0%
and 39.0%, respectively.134 These data suggest
similar effects of octreotide and lanreotide, while
no direct comparison is allowed due to the large
heterogeneity of study populations and the lack of
a randomised well-controlled head-to-head study.
Both compounds are considered equally effective in
the control of symptoms and biochemical markers
in functioning gastrointestinal NET.43 133 136 137
Antiproliferative actions of somatostatin
analogues have been claimed in various preclinical
in-vitro and in-vivo models and have been exten-
sively reviewed elsewhere.133 134 138e140 Several
retrospective series and uncontrolled studies have
suggested an antiproliferative effect of the somato-
statin analogues octreotide and lanreotide in highly
differentiated NEC.136 137 141 In a current review
analysing a total of 15 studies including 481 patients
with NET,134 patients treated with octreotide
(n¼207), octreotide LAR (n¼43), lanreotide (n¼87)
and lanreotide autogel (n¼220) exhibited tumour
response (SD+PR) in 57.4%, 69.8%, 46.6% and
64.4%, respectively.134 The most common tumour
response was stable disease, while partial response
was a rare event occurring in only 3e8% of
patients.137 Comprehensive reviews by Plockinger
and Wiedenmann136 and Strosberg and Kvols138
compared the antiproliferative effects of octreotide
or lanreotide in several clinical trials of patients with
documented progressive disease compared with
clinical trials of patients without documented
progressive disease. Plockinger and Wiedenmann136
reported in patients without documented progres-
sive disease (studies n¼8, patients n¼183) a partial
response in 8% and a stable disease in 60%, while in
patients with documented progressive disease
(studies n¼6, patients n¼201) a partial response
was seen in 3% and stable disease in 44%.136
To summarise, in these non-randomised heteroge-
neous study populations, tumour stabilisation
during therapy with somatostatin analogues was
observed in approximately 40e60%,136e138 141 with
a reported median duration of stabilisation of
9.5e26 months.136 138 Tumour stabilisation rates
are lower in patients with previously progressive
disease.136 138 Spontaneous partial tumour remis-
sions are rare events.136 137 141 The role of somato-
statin analogues for tumour control has been
controversially discussed, as these non-randomised
studies with heterogenous patient cohorts do not
allow an evidence-based judgement on a putative
antiproliferative effect of somatostatin analogues.
The placebo-controlled PROMID study has
recently demonstrated for the first time in a double-
blind, prospective, randomised trial a superior effect
of octreotide LAR against placebo in the control of
tumour growth in patients with metastatic
neuroendocrine midgut tumours.35 The PROMID
study enrolled 85 patients with metastatic neuro-
endocrine midgut tumours. The majority of all
patients demonstrated a tumour proliferation index
Ki-67 of up to 2% (95.3% of all patients), a positive
Octreoscan (74.1% of all patients) and a minor liver
tumour load of up to 10% (75.3% of all patients).
An interim analysis of the PROMID study revealed
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that the median time to tumour progression was
14.3 versus 6.0 months in the octreotide LAR group
versus the placebo group, with a HR of 0.34 (95%
CI 0.20 to 0.59; p¼0.000072).35 Stable disease at
6 months of treatment was reported in 66.7%
versus 37.2% of the patients in the octreotide LAR
group versus the placebo group.35 Nevertheless, the
PROMID data have to be interpreted with
caution.142 An imbalance in the time to diagnosis in
both treatment arms might have favoured the
octreotid LAR arm due to the enrolment of patients
with more indolent disease.142 The PROMID study
also does not answer the following clinically
important questions: (1) is it advantageous to wait
until tumour progression or to treat at initial
diagnosis? (2) is there any effect on overall survival
regarding early treatment? (3) can these data be
extrapolated to patients with NET with Ki-67
greater than 2% and hepatic tumour load greater
than 10%?.142 The NCCN guideline 200944 143 and
the NANETS guideline 201045 discuss the use of
octreotid LAR for controlling tumour growth in
functioning as well as non-functioning well-differ-
entiated NEC of jejunum/ileum as a possible ther-
apeutic option. However, use of the ‘wait and see’
strategy for a few months after initial diagnosis of
a well-differentiated asymptomatic NEC in order to
assess tumour growth dynamics is still another
option according to current guidelines.44 143
Another phase III, randomised, double-blind,
stratified comparative, placebo controlled study of
somatostatin analogues for tumour control is still
ongoing. That study will assess the effect of
lanreotide autogel 120 mg administered every
28 days on tumour PFS in patients with non-
functioning entero-pancreatic endocrine tumours
(http://ClinicalTrials.gov/ identifier: NCT00353496).
Initial therapy with short-acting octreotide
50e200 mg subcutaneously three times a day,
followed by subsequent application of slow-release
octreotide LAR 10e30 mg deep intramuscularly
every 3e4 weeks or lanreotide autogel 60e120 mg
deep subcutaneously every 4e6 weeks is recom-
mended.43 144 For the prevention and therapy of a
carcinoid crisis short-acting octreotide 50e100 mg/h
intravenously is recommended.43 144 The safety
profile of somatostatin analogues is generally
considered advantageous.45 136 144 Common side-
effects are gastrointestinal discomfort, flatulence
and steatorrhea/loose stools. Further side-effects
often include asymptomatic sludge in the gall-
bladder or cholezystolithiasis, but rarely symp-
tomatic cholelithiasis. Exocrine pancreatic
insufficiency with malabsorptive steatorrhoea and
the need for pancreatic enzyme supplementation,
as well as vitamin D deficiency should be consid-
ered during therapy with somatostatin analogues.
Bradycardia, hyperglycaemia, hypothyroidism and
vitamin B12 deficiency should also be regularly
screened for.45 136
Interferon alpha
Interferon alpha is another approved biotherapy for
symptom control and antiproliferative effects in
NEC.136 137 145 146 Interferon alpha causes a symp-
tomatic response in 30e70%;45 136 however,
demonstrating amoredelayedonset of response.45 136
The antiproliferative effects of interferon alpha have
been reviewed by Plockinger and Wiedenmann,136
analysing a total of 10 studies including 274 patients
with NET. Interferon alpha tumour response was
reported with stable disease in 70% and partial
response in 11%.136 However, these data have to be
interpreted with caution as in earlier studies the
observation time was too short.136 A current
phase III trial compared chemotherapy with strep-
tozotocin plus 5-fuorouracil versus interferon-alpha-
2a (3 MU33 per week) in 64 patients with
progressive advanced metastastic carcinoid tumours
of different primary tumour location.146 Themedian
PFS (WHO criteria, biochemical progression or
death) was 5.5 months for chemotherapy versus
14.1 months for interferon (HR 0.75 (0.41e1.36);
not significant).146
As result of numerous side-effects interferon
alpha is limited in its tolerability,136 and therefore is
currently only regarded second-line biotherapy
compared with somatostatin analogues.43 53 Three
randomised studies investigating a combination
therapy of somatostatin analogues plus interferon
alpha versus monotherapy showed a positive non-
significant trend but failed to demonstrate superi-
ority of the combination therapy.145 Therefore,
a priori combination therapy of somatostatin
analogues with interferon alpha is not recom-
mended.43 However, in patients with progressive
disease during monotherapy, combination therapy
may be an option.43 Currently used interferon
alpha dose titration regimens and recommended
monitoring for side-effects have been described
elsewhere.144
Novel biotherapeutic agents
Pasireotide (SOM-230), is a new multireceptor
ligand somatostatin analogue currently in clinical
development.147 While octreotide and lanreotide
show binding affinity mostly to the somatostatin
receptor subtypes 2 and 5, pasireotide additionally
demonstrates significant binding affinities to
somatostatin receptor subtypes 1 and 3.147 Further-
more, when compared with octreotide, pasireotide
demonstrates slightly different signalling effects. In
contrast to octreotide inducing somatostatin
receptor type 2 internalisation,148 pasireotide does
not cause somatostatin receptor type 2 internal-
isation.149e151 Pasireotide in comparison with
somatostatin not only demonstrates agonistic but
also some antagonistic effects on differential
signalling cascades.152 The clinical significance of
these different molecular findings and how they
might affect antitumoural efficacy or the develop-
ment of tachyphylaxis of pasireotid in NET needs
further evaluation. In an open-label study in patients
with inadequate control of carcinoid syndrome
during octreotide LAR, pasireotide improved
symptom control in 27%.138 A clinical phase III
study of pasireotide LAR versus octreotide LAR is
currently recruiting patients with metastatic
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carcinoid tumours whose disease-related symptoms
are inadequately controlled by somatostatin
analogues (http://ClinicalTrials.gov/ identifier:
NCT0069043).
Somatostatinedopamine chimeras may be
another future option in the biotherapy of NET.
Dopamine receptors subtype 2 have been reported
in a high percentage of low-grade NET,153 154
complementing thewell-characterised somatostatin
receptor subtypes. The somatostatin-dopamine
chimera BIM23A760 has been investigated in
a phase II clinical study in patients with carcinoid
syndrome (http://ClinicalTrials.gov/identifier:
NCT01018953), however this trial has been termi-
nated as preliminary study data did not support the
expected drug profile.
In comparison with interferon alpha, interferon
beta has a much more pronounced antitumoral
effect in NET cells in vitro.155 156 Interferon beta
inhibits the transcription of insulin-like growth
factor (IGF) type II and the IGF-IR in neuroendo-
crine BON1 tumour cells.157 This is of interest,
because the IGF system plays an essential role in
many different cancers including NEC, and most
probably contributes to the antitumoural effects of
interferon beta.157 However, its short half-life
currently prevents any clinical utility and effec-
tiveness of interferon beta as an anticancer
agent.155 Novel strategies such as pegylated inter-
feron beta or interferon beta gene transfer are
currently being developed.158
CHEMOTHERAPY
Chemotherapy of well and moderately
differentiated pancreatic NEC
Chemotherapy is an established therapeutic option
in progressive well and moderately differentiated
pancreatic NEC (see table 2) and has recently been
extensively reviewed.159 160 Standard chemotherapy
regimens in well and moderately differentiated
pancreatic NEC are streptozotocin/doxorubicin and
streptozotocin/5-fluorouracil.53 54 159 161 162 With
streptozotocin-based regimens partial response rates
of 45e65% have been reported in historical series by
Moertel et al (for review see Vilar et al).159 An
objective tumour response rate of approximately
40% with a TTP of 9e18 months has been estab-
lished in recent studies.161 164 Streptozotocin-based
protocols are still the most efficient known regi-
mens and are recommended as standard chemo-
therapy regimens.53 54 159 161 162 165
An alternative established chemotherapy
regimen is dacarbazine,159 162 with a reported
partial response rate of 35% in first-line chemo-
therapy of pancreatic NEC.166 A combination of
5-fluorouracil, dacarbazine and epirubicine has
currently been reported in a small subgroup of 16
patients with pancreatic NEC to produce a partial
response rate of up to 58%.167
Dacarbazine and temozolomide are each
converted to the same active metabolite methyl-
triazeno-imidazole-carboxamide.168 Temozolomide
as an oral chemotherapeutic agent therefore was
also evaluated in NEC.169e171 In NEC of heteroge-
nous primary tumour origin (pancreatic, small
bowel, bronchial, thymic, others) temozolomide as
a single agent caused only a partial tumour response
in 5e14% and a tumour stabilisation in 53e81%,
with amedian overall TTPof only 7e9 months.169 171
Temozolomide-based combination chemotherapies
(temozolomide/thalidomide, temozolomide/beva-
cizumab, others) have been reported in a heteroge-
nous subgroup of 53 patients with pancreatic NET
to result in a partial tumour response in 34%.170
Very promising data on temozolomide plus
capecitabine have recently been published by
Strosberg et al.172 In a series of 30 patients with
metastatic NEC of the pancreas (66% with progres-
sive disease, 33% with newly diagnosed carcinoma)
first-line chemotherapy with capecitabine (750 mg/
m2 twice a day, days 1e14) and temozolomide
(200 mg/m2 once a day at bedtime, days 10e14)
every 28 days was investigated. High efficacy of the
regimen was reported, with 70% partial remissions
and 27% stable disease, as well as a median PFS of
18 months and an estimated overall survival of 92%
at 2 years.172 Toxicity mostly consisted of myelo-
suppression, palmareplantar erythrodysesthesia,
fatigue and nausea. Overall, toxicity was moderate
with grade 3/4 toxicities and required dose reduc-
tions in only 12%, each.172 Temozolomide plus
capecitabine thus merits further evaluation in
neuroendocrine pancreatic carcinomas in rando-
mised, controlled clinical studies.
The DNA repair enzyme O6-methylguanine
DNA methyltransferase (MGMT) contributes to
the resistance of tumour cells against temozolo-
mide.168 173 174 In an immunohistochemical anal-
ysis of 97 NET samples (pancreas n¼37, bronchial
carcinoid n¼40, small intestine carcinoid n¼20)
51% of pancreatic NET but 0% of small intestine
carcinoid tumours showed MGMT deficiency.170
This finding might explain the sensitivity of
pancreatic NET but not of small intestine NET
against temozolomide.170 Whether MGMT defi-
ciency is a predictive biomarker for temozolomide
or dacarbazine sensitivity in NEC169 170 needs to be
addressed in future studies. Sensitising NET
cells against temozolomide by depleting intracel-
lular MGMT levels has been discussed as one
possible mechanism by which capecitabine might
contribute to the antitumoural synergism between
capecitabine plus temozolomide.172
Oxaliplatin-based regimens also have efficacy and
may be considered as salvage chemotherapy in
well-differentiated NEC.175 176 Bajetta et al175
reported capecitabine plus oxaliplatin in the
XELOX protocol in 27 patients with well-differen-
tiated carcinomas of different primary localisation
(lung, pancreas, small intestine, others) inducing
30% partial response and 48% stable disease, with
a median duration of remission of 20 months and
a median survival of 40 months. Preliminary
reported data with FOLFOX-6 plus bevazicumab or
CAPOX plus bevazicumab merit further investiga-
tions.177 In contrast, gemcitabine monotherapy178
and also gemcitabineeoxaliplatin in the GEMOX
protocol176 cannot be recommended in NET.
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Chemotherapy of well and moderately
differentiated NEC of the jejunum/ileum
NEC of the jeiunum/ileum are considered rather
insensitive to conventional chemotherapeutics.159
Chemotherapy with currently published regimens
is not recommended in NEC of the jejunum/ileum
according to ENETS guidelines 2008,43 NCCN
guidelines 200944 and NANETS guidelines 2010.45
Chemotherapy might only be considered for these
tumour entities when all other therapeutic options
have already been applied.44
In a large series of 249 patients with carcinoid
tumours of the small intestine treated with
doxorubicine/5-fluorouracil, streptozotocine/5-
fluorouracil or dacarbazine, Sun et al179 reported
streptozotocine/5-fluorouracil as the most efficient
regimen, with 16% partial response, 15% stable
disease and a PFS of only 5 months. A recent phase
III trial compared chemotherapy using streptozo-
tocin/5-fluorouracil with interferon alpha in 64
patients with progressive, metastatic carcinoid
tumours of the small intestine and various other
primary tumour locations.146 Overall survival in
this heterogeneous cohort was not significantly
different in both groups, but there was a trend in
favour of interferon alpha regarding median PFS.146
In the retrospective UKINETS study of 360
patients with liver metastatic midgut carcinoid
tumours chemotherapy was a negative prognostic
predictor in the univariate analysis.40
Chemotherapy of poorly differentiated NEC
Current guidelines from ENETS and NANETS
recommend cisplatin/etoposide as standard chemo-
therapy in poorly differentiated NEC with high
proliferation index Ki-67 greater than 20%.159 180 181
Moertel et al163 described in 18 patients with poorly-
differentiated NEC using etoposide/cisplatin
(etoposide 130 mg/m2 per day on days 1e3 plus
cisplatin 45 mg/m2 per day on days 2 and 3) a
complete response in 17% and a partial response in
50%, resulting in an overall tumour response rate of
67%, with a median survival of 18 months and
a median TTP of 11 months. Mitry et al182 reported
on etoposide/cisplatin (etoposide 100 mg/m2 per
day on days 1e3 plus cisplatin 100 mg/m2 per day
on day 1) in 41 patients with poorly differentiated
NEC complete response in 9.5% and partial response
in 32%. This resulted in an overall tumour response
rate of 41.5% with a median overall survival of
15 months, a median PFS of 8.9 months and a 2-year
survival of less than 20%.182 Hainsworth et al183
treated 78 patients with poorly differentiated NEC
with paclitaxel/carboplatin/etoposide. They found
a complete response in 15% and partial response in
38%, resulting in an overall tumour response rate
of 53% with 2-year and 3-year survival rates of 33%
and 24%, respectively. Paclitaxel/carboplatin/
etoposide did not show superior efficacy but a much
higher toxicity profile compared with the standard
etoposide/cisplatin.
Novel targeted therapies
Novel targeted therapies in oncology aim to target
growth factors, growth factor receptors, receptor
tyrosine kinases, or intracellular signalling cascades
in order to effect tumour angiogenesis and/or
tumour cell growth and apoptosis by inactivation of
overexpressed or overactivated signalling cascades.
NEC are hypervascularised tumours that express
growth factors and their respective receptors to
a high percentage, for example vascular endothelial
growth factor receptor (VEGFR), epidermal growth
factor receptor (EGFR), platelet derived growth
factor receptor (PDGFR), as well as insulin-like
growth factor-1 receptor (IGF-1R).184 The
phophoinositol-3-kinase (PI(3)K)eAktemTOR and
the RaseRafeMEKeErk1/2 pathway are key regu-
lators of cell survival and proliferation, activated by
various growth factors. Growth factors and their
receptors, as well as the essential PI(3)K/Akt/
mTOR and the Ras/Raf/Mek/Erk intracellular
signalling cascade,184 are thus potential targets of
novel targeted therapeutic strategies. See figure 1.
Results for novel targeted therapies from phase II
clinical studies in NET are available with bevaci-
zumab,185 sunitinib,186 everolimus,187 188 temsir-
olimus,189 imatinib,190 sorafenib and others, as has
been summarised in current reviews.184 191e193
Bevacizumab
Angiogenesis inhibition by targeting VEGF is an
established strategy in oncology and is currently
widely investigated in clinical trials in various
malignancies,194 195 while high VEGF expression is
a negative prognostic factor in various malignan-
cies.196 197 In patients with NEC198 199 high VEGF
expression has also been reported to be a negative
prognostic factor associated with increased micro-
vessel density, higher incidence of metastasis and
tumour progression as well as shorter median
PFS.198 199 Bevacizumab, a monoclonal antibody
against VEGF, significantly decreased tumour blood
flow in patients with NET.185 A prospective rand-
omised clinical phase III study of octreotide LAR
plus bevacizumab versus octreotide LAR plus
interferon alpha in advanced carcinoid patients
Table 2 Selected studies on chemotherapy in well-differentiated neuroendocrine












Moertel 1980i STZ + 5-FU 42 63 e 26 e
STZ 42 36 e 16 e
Moertel 1992j STZ + DOX 36 69 e 26 e
STZ + 5-FU 33 45 e 17 e
Kouvaraki 2004161 STZ + DOX + 5-FU 84 39 e 37 PFS 18
Fjallskog 2008164 STZ + DOX (liposomal) 30 40 57 >24 TTP 9e11
Ramanathan 2001166 Dacarbazin 50 34 e 19 e
Ekeblad 2007169 Temozolomid 12 8 67 e e
Kulke 2006k Temozolomid + thalidomid 11 45 68 >24 TTP 13
Kulke 2006l Temozolomid + bevacizumab 18 24 70 e e
Strosberg 2010172 Temozolomid + capecitabine 30 70 27 e PFS 18
Bajetta 2007175 Capecitabine + oxaliplatin (XELOX) 11 27 45 40 TTP 20
Cassier 2009176 Gemcitabine + oxaliplatin (GEMOX) 18 17 23 TTP 7
Kulke 2004178 Gemcitabine 18 0 65 11 e
Adopted from Vilar et al.159
DOX, doxorubicin; 5-FU, 5-fluorouracil; mOS, median overall survival; PFS, progression-free survival; STZ,
streptozotocine; TTP, time to progression; RR, response rate; SD, stable disease.
1018 Gut 2011;60:1009e1021. doi:10.1136/gut.2009.204453
Recent advances in clinical practice
group.bmj.com on November 20, 2014 - Published by http://gut.bmj.com/Downloaded from 
(http://ClinicalTrials.gov/ identifier: NCT00569127),
as well as phase II clinical studies of temozolomide
plus bevacizumab (http://ClinicalTrials.gov/ iden-
tifier: NCT00137774), CAPOX plus bevacizumab
(http://ClinicalTrials.gov/ identifier: NCT00398320),
FOLFOX plus bevacizumab (http://ClinicalTrials.
gov/ identifier: NCT00227617) and RAD001 plus
bevacizumab (http://ClinicalTrials.gov/ identifier:
NCT00607113) are still ongoing.
Sunitinib
Promising preliminary data of a placebo-controlled
phase III clinical study in NEC of the pancreas have
recently been presented for sunitinib. Sunitinib
(SU-11248) is a multikinase inhibitor with activity
against VEGFR-1, VEGFR-2, VEGFR-3, platelet-
derived growth factor receptor, c-Kit and Flt-3,
which is currently approved in renal cell carcinoma
and gastrointestinal stromal tumours. In a preclin-
ical model of islet cell tumours in RIP1-Tag2 mice,
sunitinib has demonstrated antitumour efficacy.200
Kulke et al186 investigated sunitinib in a clinical
phase II study in 106 patients with NEC.
In a prospective randomised clinical phase III
study of sunitinib versus placebo in advanced
pancreatic NEC patients (http://ClinicalTrials.gov/
identifier: NCT00428597) patients received either
sunitinib 37.5 mg/day continuous daily dosing
(n¼75) or placebo (n¼79).201e203 This trial was
halted prematurely due to sunitinib significantly
prolonging PFS compared with placebo.201e203
According to preliminary data presentations,201e203
PFS was 11.4 months in the sunitinib group versus
5.5 months in the placebo group (HR 0.418,
p¼0.0001).201e203 Median overall survival was not
reached, but sunitinib was favoured by a HR of
0.409 (p¼0.0204).201e203 The Committee for Medic-
inal Products for Human Use adopted sunitinib as
being indicated for the treatment of unresectable or
metastatic, well-differentiated pancreatic NET with
disease progression in adults. Experience with suni-
tinib as first-line treatment is limited. The European
Medicines Agency (EMA) approved this new indica-
tion in 11/2010 and the European Public Assessment
Report is available (http://www.ema.europa.eu).
Common side-effects of sunitinib include fatigue,
asthenia, diarrhoea, nausea, vomiting, anorexia,
bleeding complications, mucosal inflammation,
handefoot skin reaction, hypertension, anaemia,
granulocytopaenia and thrombocytopaenia.204
Another side-effect of sunitinib that clinicans
should also be aware of is hypothyroidism.204
Everolimus
The PI(3)KeAktemTOR pathway is key regulator
of cell survival and proliferation initiated by growth
factors and their activating receptor tyrosine
kinases. Activation of PI(3)K is followed by down-
stream phosphorylation of Akt and mTOR.205e208
Constitutive activation of the PI(3)KeAktemTOR
pathway is present in many malignancies including
NEC. In NEC a loss or downregulation of the expres-
sion of tumour suppressor phosphatase and tensin
homologue209 210 or of tuberous sclerosis 2210 resulting
in overactivation of the PI(3)KeAktemTOR
pathway, as well as the expression of activated
Akt211 and the expression of activated mTOR212
has been described in a high percentage of cases.
The rapamycine analogues everolimus and temsir-
olimus are mTORC-1 complex inhibitors, which
are currently approved in renal cell carcinoma.213
Preclinical in-vitro and in-vivo data in several NET
models have demonstrated that inhibition of the PI
(3)KeAktemTOR signalling cascade by the mTOR
inhibitors rapamycine214 215 and everolimus184 216
inhibits tumour cell growth and induces apoptosis.
Clinical phase II studies of mTOR inhibitors in
NEC of pancreatic and midgut origin have seen
antitumoural efficacy of temsirolimus189 and of
everolimus.187 188 In addition, in malignant insuli-
nomas fast and efficient glycaemic control by
rapamycin or everolimus217 218 has been reported in
several case reports.
In a prospective randomised clinical phase III
study of everolimus plus best supportive care versus
placebo plus best supportive care in advanced
pancreatic NEC (RADIANT-3 Study; http://Clinical
Trials.gov/ identifier: NCT00510068) patients
received either everolimus 10.0 mg/day continous
daily dosing (n¼207) or placebo (n¼203).219 220
According to preliminary data presentations,219 220
there was a 2.4-fold prolongation in median PFS
with 11.0 months in the everolimus group versus
4.6 months in the placebo group (HR 0.35,
p¼0.0001).219 220 Prolonged benefit in a subset of
patients has been suggested by estimates for
18 months PFS rates being 34% (95% CI 26% to
43%) in the everolimus group versus 9% (95% CI
4% to 16%) in the placebo group.220
In another prospective randomised clinical phase
III study of everolimus plus octreotide LAR in




























Figure 1 Diagram of phophoinositol-3-kinase (PI(3)K)eAktemammalian target of
rapamycin (mTOR) and RaseRafeMEKeErk signalling cascades and novel targeted
therapy in neuroendocrine carcinomas. EGFR, epidermal growth factor receptor; IGFR,
insulin-like growth factor receptor; IRS, insulin receptor substrate; PDGFR, platelet-
derived growth factor receptor; PDK1, phosphoinositide-dependent kinase 1; PIP2,
phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate;
PTEN, phosphatase and tensin homologue; TSC, tuberous sclerosis; VEGFR, vascular
endothelial growth factor receptor.
Gut 2011;60:1009e1021. doi:10.1136/gut.2009.204453 1019
Recent advances in clinical practice
group.bmj.com on November 20, 2014 - Published by http://gut.bmj.com/Downloaded from 
(RADIANT-2 Study; http://ClinicalTrials.gov/
identifier: NCT00412061) has been investigated.221
Patients received either everolimus 10.0 mg/day
continuous daily dosing plus octreotide LAR 30 mg
intramuscularly every 28 days (n¼216) or placebo
plus octreotide LAR 30 mg intramuscularly every
28 days (n¼213).221 According to a preliminary
data presentation,221 there was a moderate
prolongation in median PFS of 16.4 months in the
everolimus plus octreotide LAR group versus
11.3 months in the placebo plus ocreotide LAR
group (HR 0.77; 95% CI 0.59 to 1.00, p¼0.026,
which failed the prespecified significance level of
p¼0.0246).219 However, several data imbalances
may have favoured the placebo group.221 The final
data analysis and publication of this trial has to be
awaited. Approval of everolimus for NEC is
currently pending but may be expected in the
near future. Common side-effects of everolimus
known from approved indications and the current
phase III trials include stomatitis, rash, diarrhoea,
fatigue, infections, non-infectious pneumonitis,
anaemia, lymphopaenia, hypercholesterinaemia,
hyperlipidaemia and hyperglycaemia.220e222
Tumours may escape mTOR inhibition by para-
doxical activation of survival signalling path-
ways.223 Possible strategies to overcome mTOR
escape are dual blockade strategies. Accordingly,
current clinical phase II studies in NEC are sora-
fenib and everolimus (http://ClinicalTrials.gov/
identifier: NCT00942682), bevacizumab and
everolimus (http://ClinicalTrials.gov/ identifier:
NCT00607113) and erlotinib and everolimus
(http://ClinicalTrials.gov/ identifier: NCT00843531).
IGF-IR inhibition
Various further novel strategies of targeted therapy
in NEC are under development. For example, inhi-
bition of the IGF-IeIGF-IR system decreases cell
growth and promotes apoptosis in various human
NET cell lines216 224 as well as tumour control in
a xenograft model.225 Several IGF-1R antibodies
and IGF-1R tyrosine kinase inhibitors are currently
in clinical development for many different types of
cancer.224 Potential problems of in-vivo resistance
to IGF-1R inhibition need further evaluation and
caution.226 The monoclonal antibodies against
IGF-IR AMG479 (http://ClinicalTrials.gov/ identi-
fier: NCT01024387), IMC-A12 (http://ClinicalTrials.
gov/ identifier: NCT00781911) and MK-0646
(http://ClinicalTrials.gov/ identifier: NCT00610129)
are currently in clinical phase II studies in patients
with metastatic NEC.
How to choose the appropriate sequence of
therapeutic options in inoperable carcinomas?
Prognostic factors of NEC may be helpful for clin-
ical decisions and the determination of a thera-
peutic strategy. Inoperable, well-differentiated NEC
with minor/moderate tumour load in an asymp-
tomatic patient might allow an initial watch-and-
wait strategy with restaging every 3 months to
evaluate tumour growth dynamics.44 However, in
most cases the ‘wait-and-see’ strategy will result in
tumour progression as demonstrated by the
PROMID study with a median TTP of only
6.0 months in the placebo group in therapy-naive
midgut NEC.35 The watch-and-wait strategy needs
a critical re-evaluation. On the other hand, a high
initial tumour load, a symptomatic patient,
a higher proliferation index Ki-67 or a progressive
disease will necessitate initial palliative therapy.44
Evidence-based data on therapeutic sequence
Summary
This review discusses current standards as well as novel therapeutic strategies
in advanced NEC of midgut and pancreatic origin. Especially focused issues are:
< Recent comprehensive guidelines for the diagnosis and treatment of
gastroenteropancreatic NET have been published by ENETS, NCCN and
NANETS.
< It is important to consider prognostic parameters that are also useful for
therapeutic decision-making. Recommended prognostic parameters for such
purposes are differing tumour biologies of NET of the jejunum/ileum and of
pancreatic origin, different tumour gradings including proliferation index Ki-67,
the presence or absence of distant metastases, as well as the pattern and
tumour load of hepatic metastases.
< Surgery of well-differentiated NEC is recommended in local/regional disease
but also at distant disease with liver metastases. Resection of the primary
seems feasible despite liver metastases and may be beneficial especially in
NET of the jejunum/ileum, while currently not generally recommended in
panreatic NET. Resection of liver metastases or debulking more than 90% of
liver metastases is recommended and may improve overall survival.
< Neoadjuvant and adjuvant therapeutic strategies for liver surgery of hepatic
metastasised NEC are urgently needed. Further research should address this
issue.
< In well-differentiated NET of the jejunum/ileum, octreotide LAR in a randomised
placebo-controlled study caused significantly longer time to tumour
progression. Somatostatin analogues are thus no longer a standard for
symptom control in functionally active tumours, but may also be considered for
antiproliferative treatment in well-differentiated functional and non-functional
NET of the jejunum/ileum. Results of another randomised placebo-controlled
study of lanreotide autogel in enteropancreatic NET are expected in 2011.
< Streptozotocin-based regimens are still the recommended chemotherapy
standard in well-differentiated pancreatic NET. Temozolomide plus capecita-
bine may be a novel promising strategy, which merits further evaluation.
Preliminary data on oxaliplatin-based regimens (eg, XELOX, CAPOX, FOLFOX)
as second-line chemotherapy are promising, but further studies are needed.
< SIRT with 90Y-microspheres is a novel local-ablative strategy in disseminated
liver metastases. Tumour response with SIRT in NEC is comparable to results
with repetitive treatment cycles of TAE or TACE. All these local ablative
methods are recommended in inoperable hepatic metastases.
< PRRT with 90Yttrium-DOTA-TOC, 90Yttrium-DOTA-TATE and 177Lutetium-
DOTA-TATE is a promising strategy in distant metastases of NEC. PRRT
seems indicated for patients with inoperable extrahepatic with or without
intrahepatic tumour load with sufficient expression of somatostatin receptors.
< Several novel targeted therapies are currently being investigated in well and
moderately differentiated NEC. Everolimus and sunitinib have both demon-
strated improved PFS against placebo in current clinical phase III trials in NEC
of the pancreas. The European Medicines Agency (EMA) approved sunitinib
for this new indication in 11/2010. Approval of everolimus for this new
indication is currently still pending but may be expected in the near future.
< Individual multimodal therapeutic strategies in patients with NEC require
interdisciplinary decision-making in an institutionalised tumour board.
Patients should be treated in randomised controlled studies at specialised
tertiary care centres.
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strategies in inoperable metastasised NEC are not
available at present. Consensus recommendations
on possible therapeutic strategies and sequences are
provided by the recently published ENETS guide-
lines,27 43 96 144 162 227e237 NCCN guidelines,44
NANETS guidelines,45 54 238e242 European Society
for Medical Oncology (ESMO) Clinical Practice
Guidelines243 and Nordic guidelines.165
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